New COPD drug candidate shows promise in early trial
NCT ID NCT05516316
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tested whether EP395, an oral capsule, can reduce lung inflammation in healthy adults. All 49 participants inhaled a substance that causes temporary airway inflammation, mimicking a key feature of COPD. Researchers measured inflammation levels and collected safety data to see if EP395 works better than a placebo.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
EP395 (oral capsule)
What this could lead to
If it works, this could point toward a treatment that reduces lung inflammation in people with COPD.
What could go wrong
This is a very early Phase 1 trial in only 49 healthy adults, not COPD patients. The lung inflammation was artificially induced, so results may not translate to real-world COPD. The drug may also have side effects not yet seen.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC OBSTRUCTIVE PULMONARY DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fraunhofer Institute for Toxicology and Experimental Medicine ITEM
Hanover, 30625, Germany